SG11201403565XA - Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient - Google Patents
Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredientInfo
- Publication number
- SG11201403565XA SG11201403565XA SG11201403565XA SG11201403565XA SG11201403565XA SG 11201403565X A SG11201403565X A SG 11201403565XA SG 11201403565X A SG11201403565X A SG 11201403565XA SG 11201403565X A SG11201403565X A SG 11201403565XA SG 11201403565X A SG11201403565X A SG 11201403565XA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- active ingredient
- therapeutic agent
- humanized anti
- cancer therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011287654 | 2011-12-28 | ||
| JP2012133394 | 2012-06-13 | ||
| PCT/JP2012/084042 WO2013100120A1 (en) | 2011-12-28 | 2012-12-28 | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201403565XA true SG11201403565XA (en) | 2014-10-30 |
Family
ID=48697597
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201508095UA SG10201508095UA (en) | 2011-12-28 | 2012-12-28 | Humanized Anti-Epiregulin Antibody, And Cancer Therapeutic Agent Comprising Said Antibody As Active Ingredient |
| SG11201403565XA SG11201403565XA (en) | 2011-12-28 | 2012-12-28 | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201508095UA SG10201508095UA (en) | 2011-12-28 | 2012-12-28 | Humanized Anti-Epiregulin Antibody, And Cancer Therapeutic Agent Comprising Said Antibody As Active Ingredient |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9556264B2 (en) |
| EP (1) | EP2799543A4 (en) |
| JP (2) | JP6010551B2 (en) |
| KR (1) | KR20140107610A (en) |
| CN (1) | CN104136610B (en) |
| AU (1) | AU2012361510B8 (en) |
| BR (1) | BR112014015581A2 (en) |
| CA (1) | CA2862254A1 (en) |
| CL (1) | CL2014001730A1 (en) |
| CO (1) | CO7101193A2 (en) |
| CR (1) | CR20140352A (en) |
| HK (1) | HK1200187A1 (en) |
| IL (1) | IL233368A0 (en) |
| MX (1) | MX350044B (en) |
| MY (1) | MY172428A (en) |
| PE (1) | PE20141560A1 (en) |
| PH (1) | PH12014501468A1 (en) |
| RU (1) | RU2634383C2 (en) |
| SG (2) | SG10201508095UA (en) |
| TW (1) | TWI593705B (en) |
| UA (1) | UA115046C2 (en) |
| WO (1) | WO2013100120A1 (en) |
| ZA (1) | ZA201405405B (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ576855A (en) | 2006-10-12 | 2012-08-31 | Forerunner Pharma Res Co Ltd | Diagnosis and treatment of cancer using anti-ereg antibody |
| WO2010137654A1 (en) | 2009-05-29 | 2010-12-02 | 株式会社未来創薬研究所 | Pharmaceutical composition containing antagonist of egf family ligand as component |
| CN103827300A (en) | 2011-06-30 | 2014-05-28 | 中外制药株式会社 | Heterodimerized polypeptide |
| EP2772268B8 (en) | 2011-10-28 | 2020-01-08 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell-specific molecule |
| TWI593705B (en) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| ES2876009T3 (en) | 2012-12-27 | 2021-11-11 | Chugai Pharmaceutical Co Ltd | Heterodimerized polypeptide |
| AU2014299916A1 (en) * | 2013-06-24 | 2015-12-24 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent comprising humanized anti-Epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma |
| RU2714967C2 (en) * | 2013-12-27 | 2020-02-21 | Чугаи Сейяку Кабусики Кайся | Method for purifying antibodies with low isoelectric point |
| SG11201608868PA (en) * | 2014-05-01 | 2016-11-29 | Genentech Inc | Anti-factor d antibody variants and uses thereof |
| EP4056993A1 (en) * | 2014-08-20 | 2022-09-14 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring viscosity of protein solution |
| JP2019202936A (en) * | 2016-08-17 | 2019-11-28 | 中外製薬株式会社 | Combination drug of anti-Epiregulin antibody and anti-EGFR antibody |
| WO2018155611A1 (en) | 2017-02-24 | 2018-08-30 | 中外製薬株式会社 | Pharmaceutical composition, antigen-binding molecules, treatment method, and screening method |
| WO2018215535A1 (en) * | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
| GB201803892D0 (en) * | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| WO2020045545A1 (en) | 2018-08-29 | 2020-03-05 | 中外製薬株式会社 | Antibody half-molecule, and method for inhibiting homodimer formation of antibody half-molecule |
| US20220089770A1 (en) * | 2019-01-24 | 2022-03-24 | Chugai Seiyaku Kabushiki Kaisha | Novel cancer antigens and antibodies of said antigens |
| JP7232707B2 (en) | 2019-05-21 | 2023-03-03 | トーソー株式会社 | bracket structure |
| CN112574308A (en) | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | Antibodies targeting BCMA, bispecific antibodies and uses thereof |
| CN113150155B (en) * | 2021-04-22 | 2022-04-08 | 安徽瀚海博兴生物技术有限公司 | anti-PD-L1 humanized monoclonal antibody and application thereof |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5190858A (en) | 1989-02-01 | 1993-03-02 | Oncogene Science, Inc. | Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69133476T2 (en) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgenic mice capable of producing heterologous antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| CA2119930C (en) | 1991-09-23 | 2002-10-01 | Hendricus R. J. M. Hoogenboom | Production of chimeric antibodies - a combinatorial approach |
| ATE207080T1 (en) | 1991-11-25 | 2001-11-15 | Enzon Inc | MULTIVALENT ANTIGEN-BINDING PROTEINS |
| ES2227512T3 (en) | 1991-12-02 | 2005-04-01 | Medical Research Council | PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO. |
| WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100313736B1 (en) | 1993-06-04 | 2002-03-21 | 우에하라 아끼라 | Human-derived tumor cell proliferation inhibitor |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US6172213B1 (en) | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| BR9909382A (en) | 1998-04-03 | 2000-12-05 | Chugai Pharmaceutical Co Ltd | Humanized antibody against human tissue factor (tf) and humanized antibody production process |
| DE69942021D1 (en) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | GLYCOSYLATION ENGINEERING OF ANTIBODIES TO IMPROVE ANTIBODY-DEPENDENT CELL-EMITTED CYTOTOXICITY |
| PL220113B1 (en) | 1999-01-15 | 2015-08-31 | Genentech Inc | Variant of parent polypeptide comprising the Fc region, polypeptide comprising a variant of the Fc region with altered binding affinity of Fc gamma receptor (FcγR), a polypeptide comprising the variant of Fc region with altered binding affinity of neonatal Fc receptor (FcRn), a composition, isolated nucleic acid, vector, host cell, method for preparing the polypeptide variant, the use of the polypeptide variant and method for preparing a the Fc region variant |
| EP2270150B2 (en) | 1999-04-09 | 2019-08-07 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| CN100340575C (en) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| MXPA03002974A (en) | 2000-10-06 | 2004-05-05 | Kyowa Hakko Kogyo Kk | Cells producing antibody compositions. |
| CU22979A1 (en) | 2000-12-08 | 2004-09-09 | Centro Inmunologia Molecular | IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF TUMORS OVER-EXPRESSING RECEPTORS WITH KINASE ACTIVITY IN TYPOSINE WASTE |
| WO2002079255A1 (en) | 2001-04-02 | 2002-10-10 | Idec Pharmaceuticals Corporation | RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
| AU2002362197A1 (en) | 2001-12-28 | 2003-07-24 | Chugai Seiyaku Kabushiki Kaisha | Method of stabilizing protein |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| WO2003104453A1 (en) | 2002-06-05 | 2003-12-18 | 中外製薬株式会社 | Method of constructing antibody |
| EP2366718A3 (en) | 2002-06-28 | 2012-05-02 | Domantis Limited | Ligand |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| DE602004028337D1 (en) | 2003-01-22 | 2010-09-09 | Glycart Biotechnology Ag | FUSION CONSTRUCTS AND ITS USE IN ANTIBODY PRODUCTION WITH INCREASED FC RECEPTOR BINDING SAFFINITY AND EFFECTOR FUNCTION |
| US7435590B2 (en) | 2003-03-14 | 2008-10-14 | Taisho Pharmaceutical Co., Ltd. | Monoclonal antibody and hybridoma producing the same |
| US7195764B2 (en) | 2003-04-14 | 2007-03-27 | Arius Research Inc. | Cancerous disease modifying antibodies |
| PL1704166T3 (en) | 2004-01-07 | 2015-10-30 | Novartis Vaccines & Diagnostics Inc | M-csf-specific monoclonal antibody and uses thereof |
| CA2552523C (en) | 2004-01-09 | 2019-11-26 | Pfizer Inc. | Monoclonal antibodies to mucosal addressin cell adhesion molecule(madcam) |
| WO2005070963A1 (en) | 2004-01-12 | 2005-08-04 | Applied Molecular Evolution, Inc | Fc region variants |
| EP1747284A4 (en) | 2004-02-06 | 2009-03-11 | Wyeth Corp | Diagnosis and therapeutics for cancer |
| WO2006020114A2 (en) | 2004-08-04 | 2006-02-23 | Applied Molecular Evolution, Inc. | Variant fc regions |
| JP2008510008A (en) | 2004-08-16 | 2008-04-03 | メディミューン，インコーポレーテッド | Integrin antagonists with enhanced antibody-dependent cellular cytotoxicity |
| RU2367667C2 (en) | 2004-08-19 | 2009-09-20 | Дженентек, Инк. | Polypeptide variants with changed effector function |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| WO2006067847A1 (en) | 2004-12-22 | 2006-06-29 | Chugai Seiyaku Kabushiki Kaisha | Method of preparing antibody by use of cell having its fucose transporter function inhibited |
| CN101365712A (en) | 2005-01-11 | 2009-02-11 | 莫勒丘尔洛吉克斯有限公司 | Pan-her antagonists and methods of use |
| EP1871808A2 (en) | 2005-03-31 | 2008-01-02 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| JP5255435B2 (en) | 2005-04-26 | 2013-08-07 | メディミューン，エルエルシー | Regulation of antibody effector function by hinge domain manipulation |
| JP4989476B2 (en) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Methods for assaying the effects of angiogenesis inhibitors |
| WO2007021841A2 (en) | 2005-08-10 | 2007-02-22 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| EP1931709B1 (en) | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| WO2007092932A2 (en) | 2006-02-08 | 2007-08-16 | Targeted Molecular Diagnostics, Llc | Bivalent erbb ligand binding molecules and methods for their preparation and use |
| US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| NZ576855A (en) * | 2006-10-12 | 2012-08-31 | Forerunner Pharma Res Co Ltd | Diagnosis and treatment of cancer using anti-ereg antibody |
| EP3239175A1 (en) | 2007-01-05 | 2017-11-01 | University of Zurich | Method of providing disease-specific binding molecules and targets |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| JP2009078946A (en) | 2007-09-26 | 2009-04-16 | Fujifilm Corp | Core-shell type metal oxide particle and method for producing the same |
| CA2700394C (en) | 2007-09-26 | 2017-10-24 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
| DK2196541T3 (en) | 2007-09-28 | 2012-11-26 | Chugai Pharmaceutical Co Ltd | Anti-glypican-3 antibody with improved plasma kinetics |
| WO2010137654A1 (en) | 2009-05-29 | 2010-12-02 | 株式会社未来創薬研究所 | Pharmaceutical composition containing antagonist of egf family ligand as component |
| GB0909906D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
| GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
| WO2012046797A1 (en) | 2010-10-06 | 2012-04-12 | ファーマロジカルズ・リサーチ プライベート リミテッド | Cancer stem cell mass and process for production thereof |
| CN103827300A (en) | 2011-06-30 | 2014-05-28 | 中外制药株式会社 | Heterodimerized polypeptide |
| TWI593705B (en) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
| AU2014299916A1 (en) | 2013-06-24 | 2015-12-24 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent comprising humanized anti-Epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma |
-
2012
- 2012-12-26 TW TW101150028A patent/TWI593705B/en not_active IP Right Cessation
- 2012-12-28 CA CA2862254A patent/CA2862254A1/en not_active Abandoned
- 2012-12-28 MX MX2014008009A patent/MX350044B/en active IP Right Grant
- 2012-12-28 AU AU2012361510A patent/AU2012361510B8/en not_active Ceased
- 2012-12-28 PE PE2014001036A patent/PE20141560A1/en not_active Application Discontinuation
- 2012-12-28 SG SG10201508095UA patent/SG10201508095UA/en unknown
- 2012-12-28 BR BR112014015581-0A patent/BR112014015581A2/en not_active IP Right Cessation
- 2012-12-28 CN CN201280070788.2A patent/CN104136610B/en not_active Expired - Fee Related
- 2012-12-28 JP JP2013551852A patent/JP6010551B2/en not_active Expired - Fee Related
- 2012-12-28 US US14/369,539 patent/US9556264B2/en not_active Expired - Fee Related
- 2012-12-28 SG SG11201403565XA patent/SG11201403565XA/en unknown
- 2012-12-28 WO PCT/JP2012/084042 patent/WO2013100120A1/en active Application Filing
- 2012-12-28 RU RU2014130766A patent/RU2634383C2/en not_active IP Right Cessation
- 2012-12-28 UA UAA201408353A patent/UA115046C2/en unknown
- 2012-12-28 MY MYPI2014701733A patent/MY172428A/en unknown
- 2012-12-28 EP EP12863154.6A patent/EP2799543A4/en not_active Withdrawn
- 2012-12-28 KR KR20147020786A patent/KR20140107610A/en not_active Application Discontinuation
-
2014
- 2014-06-25 PH PH12014501468A patent/PH12014501468A1/en unknown
- 2014-06-25 IL IL233368A patent/IL233368A0/en unknown
- 2014-06-26 CL CL2014001730A patent/CL2014001730A1/en unknown
- 2014-07-22 CR CR20140352A patent/CR20140352A/en unknown
- 2014-07-22 ZA ZA2014/05405A patent/ZA201405405B/en unknown
- 2014-07-24 CO CO14161083A patent/CO7101193A2/en unknown
-
2015
- 2015-01-16 HK HK15100507.9A patent/HK1200187A1/en not_active IP Right Cessation
-
2016
- 2016-09-15 US US15/266,829 patent/US20170129950A1/en not_active Abandoned
- 2016-09-16 JP JP2016181435A patent/JP6329601B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1200187A1 (en) | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient | |
| HK1252481A1 (en) | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | |
| HK1203309A1 (en) | Antibody drug conjugates and related compounds, compositions, and methods | |
| IL231386A (en) | Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof | |
| IL228738B (en) | Anti-cldn6 antibody, a pharmaceutical composition comprising it and use of same | |
| BR112014009634A2 (en) | preparation and therapeutic agent | |
| EP2868667A4 (en) | Therapeutic agent for anemia including renal anemia and cancer-induced anemia which contains anti-bmp9 antibody as active ingredient | |
| SG2014008304A (en) | C10rf32 antibodies, and uses thereof for treatment of cancer | |
| EP2792746A4 (en) | Oligonucleotide and therapeutic agent for hyperlipidemia containing same as active ingredient | |
| EP2773637A4 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| ZA201209145B (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
| EP2666475A4 (en) | Therapeutic agent for alopecia | |
| IL227558A0 (en) | Therapeutic agent for tumor | |
| ZA201308186B (en) | Solid, particulate tanning agent preparations | |
| IL231444A0 (en) | Aniline derivativs, their preparation and their therapeutic application | |
| EP2729008A4 (en) | Systems, methods, and formulations for treating cancer | |
| HK1223567A1 (en) | Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma | |
| IL233238A (en) | Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application | |
| HK1215959A1 (en) | Anti-cdh3 humanized antibody, drug conjugate thereof, and utilization of same cdh3 | |
| EP2843051A4 (en) | Anti-human cd69 antibody, and use thereof for medical purposes | |
| IL220859A0 (en) | Alkyl-heterocycle-carbamate derivatives, their preparation and therapeutic application | |
| EP2781521A4 (en) | Novel spiroindoline compound, and medicinal agent comprising same | |
| IL232339A0 (en) | C10rf32 antibodies , and uses thereof for treatment of cancer | |
| BR112014005011A2 (en) | compound, treatment methods and pharmaceutical composition |